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Abstract. Twenty-three patients with pituitary adrenocorticotropic hormone 
(ACTH)-dependent Cushing’s syndrome were studied before and after treatment. 
The relationship between the amelioration of the depressive syndrome and changes 
in cortisol and ACTH levels was investigated. There was asignificant difference in 
mean change in 24-hour urinary free cortisol (UFC) excretion for changes in the 
depressed mood score from first to last visit. There were also significant 
correlations between decreases in UFC and decreases in both the depressed mood 
score and the modified Hamilton depression score. These relationships were not 
found for ACTH. Furthermore, with cortisol decreased to normal levels, 
continued high ACTH levels did not prevent improvement in depressed mood. The 
possibility that cortisol may also play a role in the pathogenesis and/or 
maintenance of the mood disorder in psychiatric patients is discussed. 
Key Words. Gushing’s syndrome, depressed mood, symptom remission, cortisol, 
adrenocorticotropic hormone. 
Assessment of the hypothalamic-pituitary-adrenal axis has become important in 
psychiatry. The dexamethasone suppression test (DST) is a major investigative tool in 
the evaluation of patients with primary affective disorder (Carroll et al., 1981). In 
addition, patients with a wide variety of psychiatric diagnoses who are DST 
nonsuppressors have been found to be more symptomatic on admission (e.g., anxiety, 
sleep disorder, difficulty with attention, and low energy) than patients who are DST 
suppressors (Reus, 1982). 
Cushing’s syndrome is, of course, the classic disease in which hypersecretion of 
cortisol and diminished suppression of cortisol by dexamethasone are pathognomonic 
features. Emotional disturbance is also present in Cushing’s syndrome, and has been 
recognized as a feature of the disease since Harvey Cushing’s original description in 
1932. In a study of 35 unselected consecutive patients with Cushing’s syndrome, we 
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described a constellation of psychiatric symptoms including impairment in affect 
(depressed mood and crying), cognitive functions (decreased concentration and 
memory), and vegetative functions (decreased libido and insomnia) (Starkman et al., 
1981). Additional symptoms of greater severity such as paranoid and confusional 
states were much less frequent and were associated with particularly high levels of 
cortisol and adrenocorticotropic hormone (ACTH) (Starkman and Schteingart, 
198 1). The psychiatric symptoms that develop in Cushing’s syndrome and the quality 
of the symptoms argue for a pathogenesis over and above a nonspecific response to 
severe physical illness. Irritability and decreased libido occur early, often before 
patients are aware that they have any physical problems other than a steady increase in 
weight. Depressed mood is experienced not simply as the demoralization common to 
patients with medical illness, but also as episodic sadness and crying often occurring in 
the absence of depressive thought content. In addition, the characteristic disorders of 
memory and concentration occur in patients who have no disorientation or overt 
clouding of consciousness. 
We now report our findings in 23 patients with spontaneous pituitary ACTH- 
dependent (PAD) Cushing’s syndrome studied longitudinally from time of diagnosis 
through treatment. Our results indicate that improvement in the depressive syndrome 
is associated with treatment that effectively lowers levels of cortisol, despite continued 
high levels of ACTH. 
Methods 
Patients. Twenty-three patients with PAD Gushing’s syndrome studied psychiatrically before 
medical treatment were available for reevaluation after treatment was initiated. Three patients 
were black; the remainder, white. Of these patients, 5 were male and 18 were female, 
approximating the ratio of male to female usually seen in this disorder. The age range was 19-60 
years, with a mean of 36.9 years and a median of 35 years. 
The initial diagnosis of Gushing’s syndrome was established by clinical criteria plus the 
demonstration of excessive cortisol secretion as measured by abnormalities in urinary free 
cortisol, cortisol secretion rate, and plasma cortisol; absence of normal circadian rhythm of 
cortisol; and failure to suppress normally after 2 mg of dexamethasone. While in a few 
individual cases one or another hormone level fell within the normal range, the other parameters 
listed above made the diagnosis clear. Before treatment, the etiological type of Cushing’s 
syndrome had been determined for each patient on the basis of baseline cortisol and ACTH 
levels, as well as the ACTH response to dexamethasone suppression and metyrapone 
stimulation. The 23 patients with PAD Cushing’s syndrome did not have a radiographically 
detectable pituitary tumor. 
The patients received treatment with mitotane, a drug that acts by blocking steroid 
biosynthesis directly at the level of the adrenal gland (Schteingart et al., 1980). In addition, the 
patients received pituitary irradiation, a treatment that was expected, after several years, to 
produce an eventual decline in ACTH production. One patient was treated with transphenoidal 
pituitary surgery only. 
Patients were evaluated at variable intervals once treatment began. Since patients entered the 
study in a consecutive fashion, some had been followed for longer periods of time, some for 
shorter periods. The number of months elapsed between the first and last recorded visit was 
therefore variable, ranging between 2 and 72 months, with a mean and a median each of 24 
months. 
Psychiatric Evaluation. The details of the semistructured psychiatric interview have been 
described previously (Starkman et al., 1981). Forty-five items covering affective, vegetative, 
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and cognitive disturbances were studied by symptom report and/or observation during mental 
status examination. Items studied by symptom report were scored on the basis of the patient’s 
experience of the symptom in the 4 weeks before the evaluation, as described to the examiner 
(MNS). Although the Research Diagnostic Criteria (RDC) are prohibited for use with such 
patients because of the existence of a specific organic disease causing both physical and mental 
symptoms, many items from the RDC were incorporated into the structured portion of the 
interview. For the followup visits, particular attention was given to the change in each item 
studied, such as depressed mood, with regard to the patient’s description of alteration in quality, 
intensity, and frequency. Each symptom was scored separately on the same 4-point rating scale 
(absent, mild, moderate, or severe) established for the initial evaluation. Symptoms were further 
characterized as having improved, worsened, or remained the same compared to the prior visit. 
We also used the Hamilton Rating Scale for Depression, a composite of the affective, 
vegetative, and cognitive items which constitute the depressive syndrome. We modified the 
standard Hamilton score (Hamilton, 1967) by omitting items 12, 15, 16, and 17, which are either 
not appropriate in patients with Cushing’s syndrome (hypochondriasis, loss of insight) or 
involve gastrointestinal symptoms and weight loss that could be affected by the pharmaco- 
therapy with mitotane. Thus, these scores are useful for the longitudinal comparisons that are 
the focus of this article, but should not be taken as equivalent to standard Hamilton depression 
scores. 
The depressed mood score, derived from the patient’s self-report of degree of depressed 
mood, and the modified Hamilton score were usually (although not always) of the same relative 
magnitude. Spearman’s rank-order correlation did show a statistically significant correlation 
between the depressed mood score and the modified Hamilton depression score (p = 0.77, 
p<O.OI). 
At both the initial and followup psychiatric evaluations, the evaluator (M.N.S.) was unaware 
of the hormone levels of the patient. 
Hormone Analysis. Plasma samples for ACTH were obtained several times during the day for 
assessment of circadian rhythm. Values were found to vary little during the day, a characteristic 
of Cushing’s syndrome, both at initial and followup evaluations. Although efforts were made to 
obtain the entire set of hormone levels for each patient at each visit, in several instances, a 
particular hormone level was not available because of technical difficulties (usually the IO p.m. 
sample). Since the 8 a.m. samples were available most consistently, these values were used for 
the statistical analysis of plasma ACTH levels. 
Twenty-four-hour urinary free cortisol excretion, an integrative measure of cortisol, was 
measured by radioimmunoassay (Dash et al., 1975). 
Plasma ACTH was measured by radioimmunoassay, using the method of Vague et al. (I 97 I). 
The antiserum for this assay was generously provided to us by Vague, is used at a dilution of 
I :SOO,OOO, has a low cross-reactivity with other peptides, and is capable of detecting ACTH in 
plasma in concentrations as low as 6 pg/ ml. Separation of free from bound hormone is carried 
out with I .5% charcoal suspension. The trace is prepared using extracted human ACTH l-39 
provided by C.H. Li and iodinated with 1251 by the chloramine T method of Hunter and 
Greenwood (1962). Each sample is run in four dilutions. Nonparallel samples are reassayed and, 
if necessary, extracted and purified by Sephadex GSO column fractionation before radio- 
immunoassay. Quality control studies are carried out with each assay using standard sera and 
carryover samples from previous assays. The coefficient of variation is 4.2% + I .2% for 20% 
binding, and 8.4% f 2.4% for 80% binding. The same antiserum and assay method was used for 
all samples. 
Statistical Analysis. The raw values of hormone levels in plasma and urine were not normally 
distributed. Log transformations gave distributions with better fit to normal distributions and 
were, therefore, used for the analyses. A one-way analysis of variance was used to ascertain 
whether there were statistically significant differences in mean changes in 24-hour urinary free 
cortisol and in ACTH for changes in the depressed mood symptom score from first to last visit 
(categorized as improved, no change, or worse). Analysis of covariance with time elapsed from 
180 
first to last visit as a covariate was also used. For this analysis, change in depressed mood score 
was categorized by the magnitude of the change in point score from first to last visit (0, + I, +2, 
f3). Multiple regression analyses using the modified Hamilton depression scores (categorized 
by magnitude of change in point score from first to last visit: -4 to -I, 0 to 2,3 to 9, IO to 14) as the 
dependent variable and urinary free cortisol and ACTH as the independent variables were 
computed. 
Pearson’s product-moment correlation coefficients were used to study the relationship of 
changes in modified Hamilton depression scores from first to last visit with changes in cortisol 
and ACTH levels. Nonparametric Spearman rank-order correlations were used to study the 
relationship of changes from first to last visit in symptoms such as depressed mood, which were 
scored on a 4-point ordinal scale, with changes in cortisol and ACTH levels. Results are 
reported as mean + SD. 
Results 
Remission of Hypercortisolemia. Twenty-four-hour urinary free cortisol (UFC) is 
used as an integrative measure of cortisol excretion. By 3 months after the initiation of 
treatment, 9 of 23 (39%) patients had normal UFC excretions. By 6 months, 18 of 23 
(70%) had normal UFC excretions. The mean number of months from the evaluation 
and initiation of treatment to normalization of cortisol levels, as measured by 24-hour 
UFC excretion, was 9. The range was l-42 months, with a median of 5 months. At their 
last visit and the psychiatric evaluation reported here, I7 patients (73%) had normal or 
low cortisol levels. In contrast, only eight patients (35%) had normal or low ACTH 
levels. The circadian rhythm of ACTH and cortisol secretion was still absent for most 
patients at the last visit. 
UFC and ACTH values at 8 a.m. are shown individually in Table 1. At the initial 
visit, mean UFC was 689.6 + 639 (normal range: 30-100 pg/day). At the last visit, 
mean UFC was 89 + 6 1.3. This difference is statistically significant @ < 0.001). At the 
initial visit, mean ACTH was 210.3 * 195 (normal range: 52-92 pg/ml). At the last 
visit, mean ACTH was 214.2 + 315.6. This difference is not statistically significant. 
Improvement in Depressed Mood: Qualitative Description. In our initial study, 
we characterized the mood disturbances in untreated spontaneous Cushing’s syn- 
drome (Starkman et al., 198 1). Depressed mood was present in 75% of the patients in 
the sample. Many patients stated that they would wake up depressed and remain 
depressed throughout the day or the next day as well. Alternatively, the onset of 
depressed mood and/ or crying might occur during the day. Patients stressed that the 
onset of depression could be sudden, at times with a rapid shift at some point during 
the day. Some patients described hypersensitivity and oversentimentality as 
determinants leading to crying spells. For some patients, crying was experienced as 
their only available behavioral response to anger, frustration, and feelings of inability 
to respond effectively. Patients also described the spontaneous onset of depressed 
mood or crying in the absence of any preceding upsetting thought or event. There was 
a range in the intensity of depressed mood. Some patients described short spells of 
sadness; others experienced feelings of hopelessness and giving up. Six patients had 
had suicidal thoughts, and two of these patients had made suicide attempts since the 
onset of the Cushing’s syndrome. Social withdrawal, when present, was related to 


























































































































































































































































































































































































































































































































































































































physical appearance and did not wish to be seen in public. Moreover, the unstructured 
setting of a large group elicited a decreased sense of focus, alertness, and clarity that 
led to a generalized sense of uneasiness. Most patients reported an increased desire to 
have contact with significant family members. As noted previously, however, sporadic 
withdrawal might occur because of the patient’s need to remove him/ herself from the 
situation of overstimulation that elicited the fear of impending emotional dyscontrol. 
Guilt, when present, was not excessive, self-accusatory, or irrational. It was related 
primarily to remorse about the frequent and uncontrollable angry outbursts and 
inability to function as well as previously at work and in the family. Hopelessness, 
when present, was attributed to the existence of a chronic illness with increasing 
physical and emotional disability that so far had proved undiagnosable and 
untreatable. The time course of the mood disturbances was noteworthy. Patients 
reported that their mood disturbances were intermittent rather than sustained. 
Although there were intervals when they felt lack of pleasure, these patients did not 
describe persistent anhedonia. They did not experience the unrelenting, unremitting 
inability to experience pleasure that is characteristic of patients with melancholic 
major depressive illness. There were intervals when they retained the capacity for 
pleasure and found enjoyment in hobbies, activities, and interpersonal relationships. 
At times, some patients found it difficult to initiate such activities; once others 
mobilized them, they would enjoy them. The duration of each depressive episode was 
usually 1 to 2 days and rarely longer than 3 days at a time. A frequent weekly total of 
dysphoria was reported as being 3 days per week. There was no regular cyclicity, 
however, so that patients could not predict when a day of depression would occur. 
In the treated patients, improvements in depressed mood were characterized by a 
decrease in the frequency of days when the patient felt depressed. In addition, each 
episode would last a shorter period of time, perhaps only a few hours instead of a day 
or two. The patients also described a change in quality of the depressive mood, so that 
they no longer experienced being in a “total depression,” or felt that it was “deep” or 
all-encompassing. They no longer became depressed without some external pre- 
cipitating event. They noted that now the mood change came on gradually and 
disappeared gradually rather than appearing suddenly as before. Crying was less 
frequent, less easily elicited by environmental upsets, occurred only with some 
identifiable external precipitant, and was of shorter duration. 
Improvement in Depressed Mood Scoresand Modified Hamilton Depression 
Scores. At the first visit (pretreatment), 18 of 23 (78%) patients with PAD Cushing’s 
syndrome reported depressed mood. At the last visit, 9 of these 18 patients reported 
normal mood, while an additional four reported improvement in depressed mood. 
The remaining five patients reported no improvement in depressed mood, although in 
three of the five the modified Hamilton score had improved by 30% or more. The 
difference (decrease) in mean depressed mood score from first to last visit was 
statistically significant 0, < 0.001). 
Modified Hamilton depression scores and depressed mood scores at the first and 
last visits are given for each patient in Table I. At first visit, 14 of 23 patients had 
modified Hamilton scores 3 IO. At last visit, five patients had modified Hamilton 
scores of 3 10. Of these five, three had been treated < I year. The mean modified 
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Hamilton depression score was 10.8 + 5.8 at the initial visit, and 5.5 + 4.8 at the last 
visit. The difference (decrease) in mean modified Hamilton depression score from first 
to last visit was statistically significant @ < 0.001). 
Relationship of Depressed Mood Scores and Modified Hamilton Depression 
Scores to Changes in Hormone Levels. For the first visit (pretreatment), an 
analysis of variance revealed no significant differences in mean UFC or mean ACTH 
levels for the four depressed mood intensity categories (absent, mild, moderate, or 
severe). For individuals with UFC levels3 lOOOyg/day, mean UFC was 1639,ug/day, 
and mean modified Hamilton was 14.5. For individuals with UFC levels between 100 
and 10001ug/day, mean UFC was 369pg/day and mean modified Hamilton was 10.7. 
For individuals with UFC levels < lOOpg/day, mean UFC was 86pg/day, and mean 
modified Hamilton was 4. The modified Hamilton depression scores at the first 
pretreatment visit showed a weak correlation with UFC (r = 0.39, p = 0.08). 
Inspection of Table I indicates that at the higher levels of 24-hour UFC, higher 
modified Hamilton scores occurred consistently, but at the lower levels of 24-hour 
UFC elevation, modified Hamilton scores could be either high or low. 
Several statistical tests were used to study the relationship of changes in the 
depressed mood score and in the modified Hamilton score with the changes in 
hormone levels that were brought about by treatment. ANOVA revealed that there 
was a statistically significant difference in mean change in UFC excretion for changes 
in depressed mood score from first to last visit (F= 5, df = 2/ 18, p < 0.05). To study 
whether these differences remain significant after adjustment for the length of time 
patients were in the study, an analysis of covariance, using time in months elapsed 
from first to last visit as a covariate, was done. There was a significant effect of time. 
Nevertheless, the analysis revealed that covarying on time did not reduce the 
significance of the differences in mean UFC levels for the different mood score 
changes. 
Correlational analyses were also completed. Spearman’s rank-order correlation 
showed a statistically significant correlation between change (decrease) in UFC from 
first to last visit and change (decrease) in the depressed mood score @ = 0.67, p < 
0.0 I). Pearson’s product-moment correlation showed a statistically significant 
correlation between change (decrease) in the 24-hour UFC excretion from first to last 
visit and change (decrease) in the modified Hamilton depression score (r = 0.66, 
p < 0.001). Similarly, there was a statistically significant correlation of change 
(decrease) in UFC excretion measured as % change and change (decrease) in the 
modified Hamilton depression score (r = 0.57, p < 0.01). 
In contrast to these findings with cortisol, analyses of variance for ACTH revealed 
no significant differences in either mean absolute or yc change in ACTH for change in 
depressed mood scores from first to last visit. In addition, there was no significant 
correlation between changes in ACTH level and change in the depressed mood scores 
or the modified Hamilton depression scores from first to last visit. 
Conjoint Relationship of Cortisol and ACTH and Depressed Mood. Multiple 
least-squares regression analysis of the change in the modified Hamilton score on the 
change in both UFC and ACTH was statistically significant (F= 9.4, df = 2/ 18, p < 
184 
0.01) with the change in UFC being the only significant contributor (t = 4.1, p < 
0.00 I). 
To explore further the conjoint relationship of cortisol and ACTH to depressed 
mood, the improvement in depressed mood score and modified Hamilton depression 
score in patients whose cortisol and ACTH levels had both normalized by the last visit 
was compared with that of patients in whom only cortisol levels were normalized while 
ACTH levels remained elevated. Of the six patients with depressed mood at first visit 
who subsequently demonstrated both normal UFC and ACTH levels at the last visit, 
five of six showed improvement in the depressed mood score. Of the nine patients with 
depressed mood at first visit who showed normal UFC levels but continued to have 
elevated ACTH levels at the last visit, six showed improvement in depressed mood 
scores despite the continuing elevation of ACTH, while three showed no improvement. 
Six of six patients who achieved both normal UFC and normal ACTH levels 
showed a decrease of 3 30% in the modified Hamilton score. Of the nine patients who 
achieved normal UFC but continued to have elevated ACTH levels, eight showed a 
decrease of 3 30% in the modified Hamilton score. 
While the numbers are small, it is apparent that with cortisol decreased to normal 
levels, continuing high ACTH levels did not prevent improvement in depressed mood 
and in the depressive syndrome as measured by the modified Hamilton score. 
Improvement in Other Neuropsychiatric Symptoms. Change in neuropsychia- 
tric symptoms was studied by examining the percent of patients affected with a 
particular symptom at the initial visit who showed improvement in that symptom at 
the last visit, as measured by a decrease in the rating score for that symptom. 
There was a definite improvement in psychiatric symptoms with treatment. This 
improvement was not uniform, however, and there was variability among symptoms 
in the percent of affected individuals who showed improvement with treatment. In 
comparison to the 72% (13/ 18) of affected patients reporting improvement in 
depressed mood from first to last visit, 80% of affected individuals reported 
improvement in concentration, 78% in late insomnia, 70% in memory, 68% in 
irritability, 62% in middle insomnia, and 28% in libido. 
Relationship of Improvement in Other Neuropsychiatric Symptoms to 
Changes in Hormone Levels. Statistical tests were used to study the relationship of 
changes in other neuropsychiatric symptoms with changes in hormone levels brought 
about by treatment. For those patients demonstrating the particular symptom at the 
first visit, ANOVAs revealed that there were statistically significant differences in 
mean changes of 24-hour UFC excretion for changes in scores from first to last visit 
(categorized as improved, no change, or worse) for: energy level (increased) and UFC 
excretion (decreased) (F = 7.7, df = 2/ 19, p < 0.05); libido (increased) and UFC 
excretion (decreased) (F= 6.3, df = 2/ 10, p < 0.05); concentration (increased) and 
UFC excretion (decreased) (F= 3.6, df = 2/ 17, p < 0.05). There were no significant 
differences in mean changes of ACTH levels for changes in any of the above 
mentioned symptoms. For late insomnia, there were statistically significant differ- 
ences in mean changes (decreases) in both UFC (F= 3.8, df = 2/ 15, p < 0.05) and 
ACTH (F = 8.3, df = 2/ 15, p < 0.01) for changes in score from first to last visit. 
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Correlational analyses were also performed. There were statistically significant 
correlations for change (improvement) in energy and change (decrease) in UFC 
@ = 0.48, p < 0.01); change in middle insomnia and change in UFC @ = 0.77, 
p < O.OOl), and change in concentration and change in UFC @ = 0.50, p < 0.05). 
Changes in ACTH showed no significant correlations with changes in any of the 
symptoms studied. 
Discussion 
In our previous study of patients with untreated Cushing’s syndrome, the data 
suggested that when cortisol levels were elevated before treatment, low or normal 
ACTH levels were associated with mild rather than pronounced depressed mood, 
while elevated ACTH levels were equally likely to be associated with mild or 
pronounced depressed mood (Starkman et al., 1981). In the current study, we were 
able to achieve some pharmacological dissection of the relationship of ACTH and 
cortisol levels and depressed mood. The patients were treated with mitotane, an 
adrenolytic drug which promptly blocks steroid synthesis directly at the level of the 
adrenal gland, decreasing cortisol levels while ACTH levels do not change or may even 
rise above the pretreatment levels in patients with pituitary ACTH-dependent 
Cushing’s syndrome. Concomitant pituitary irradiation then often produces an 
eventual decline in ACTH production but only after a period of several years. 
At the pretreatment visit, there was a trend toward a weak correlation of the 
modified Hamilton depression scores and UFC. However, using the four-point rating 
scale for depressed mood score, we did not find a significant relationship between the 
depressed mood score and UFC. It cannot be determined whether the lack of a 
significant relationship is due to insufficient variability in depressed mood at the first 
visit, insensitivity of the four-point rating scale used, or the possibility that once a 
threshold of cortisol elevation is reached, the absolute level of cortisol is not related to 
the degree of depressed mood. These results are consistent with those in patients with 
primary affective disorder. Using a modified Bunney-Hamburg Scale, Rubinow et al. 
(1984) found that only in a minority of such patients was a correlation seen when 
plasma cortisol values were examined just in the depressed state, and the significant 
correlation was highly dependent on values in both the depressed and improved state. 
Our study suggests an association of improvement in depressed mood and decrease 
in cortisol from pretreatment values. Kelly et al. (1983), in a series of 26 patients with 
Cushing’s syndrome, found significant improvement in depression as measured by 
improvement in the Hamilton Rating Scale for Depression after treatment produced 
decreases in cortisol levels, although these investigators could not demonstrate a 
significant correlation between changes in UFC and depression ratings either at 3 or I2 
months. In the studies reported here, our analysis of covariance revealed a significant 
effect of time, complementing the impression from previous case reports of patients 
with adrenal adenomas that there may be a delay of months to years from the 
correction of elevated cortisol levels to complete remission of psychiatric symptoms 
(Haskett, 1985). 
Further, the results of our study indicate that with normal cortisol levels achieved by 
treatment, depressed mood and the depressive syndrome can improve despite the 
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continuation of elevated ACTH levels. This observation is supported by two recent 
studies reporting improvement of depression in patients with pituitary-dependent 
Cushing’s disease, many of whom were treated with bilateral adrenalectomy or 
metyrapone, an I l-fi-hydroxylase inhibitor that blocks cortisol biosynthesis by the 
adrenal gland (Jeffcoate et al., 1979; Cohen, 1980). While ACTH was not measured in 
these two studies, treatment with either metyrapone or bilateral adrenalectomy does 
characteristically result in further increases in the already high plasma ACTH levels 
despite adequate corticosteroid replacement where necessary. 
The present study lends support to the hypothesis that the behavioral changes of the 
depressive syndrome seen in Cushing’s syndrome may be at least partly related to the 
effect of elevated levels of cortisol. It is unknown whether this reflects adirect effect on 
the cells of the central nervous system, on neurotransmitters, or on intracellular 
electrolytes due to increased sensitivity of the brain to elevated levels of P-endorphin, 
ACTH, or corticotropin-releasing factor (CRF), or some other mechanism. 
Evidence is accumulating that corticosteroids affect a wide variety of enzymes 
important in neurochemistry, and may alter mood-regulating neurotransmitter 
systems within the brain. In animals, hydrocortisone increased liver tryptophan 
pyrolase with a subsequent decrease in brain tryptophan and serotonin (Green and 
Curzon, 1968). In tissue culture, hydrocortisone and dexamethasone stimulated 
tyrosine hydroxylase, the rate-limiting enzyme in catecholamine synthesis, and 
inhibited choline acetyltransferase, markedly inhibiting the synthesis of acetylcholine 
(Schubert et al., 1980). In rat brain, corticosteroids altered the sensitivity to 
noradrenalin of the noradrenalin receptor-coupled adenylate cyclase system (Mobley 
and Sulser, 1980). Anatomical evidence for the role of cortisol in regulating mood 
comes from the observation that in rat brain, the highest concentration of binding sites 
for 3H-corticosterone is found not in the hypothalamus but in the limbic system: 
hippocampus, amygdala, and septum (McEwen et al., 1975). 
Studies in patients with primary psychiatric disorders also indicate that increased 
cortisol levels are associated with both behavioral and physiological abnormalities. 
Psychiatric inpatients with high 8 a.m. values of plasma cortisol, regardless of whether 
they had primary endogenous depression or some other psychiatric diagnosis, were 
more symptomatic on admission, and on discharge had more symptoms of sleep 
disturbance and decreased ability to think than patients with normalvalues of plasma 
cortisol (Reus, 1982). Several investigators have reported extremely high UFC levels 
in subgroups of depressed patients who subsequently attempted suicide (Bunney et al., 
1969; Ostroff et al., 1982). Gerner and Wilkins (1983) have recently confirmed 
previous observations that cerebrospinal fluid (CSF) cortisol levels are elevated in 
depressed patients as compared to normals, and that there is a correlation of CSF 
cortisol and the severity of depression. As regards physiological effects, evidence for 
the existence of somatic effects of glucocorticoid excess in depressed DST non- 
suppressors, as measured by discriminant function analysis of hematological cellular 
and blood chemistry findings, has been reported (Reus and Miner, 1985). A decreased 
sensitivity of lymphocytes to glucocorticoid-induced immunosuppression has been 
found in depressed patients as well, possibly due to down-regulation of the 
lymphocyte glucocorticoid receptor (Lowy et al., 1984). 
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In summary, we studied 23 patients with PAD Cushing’s syndrome before and after 
treatment. Improvement in depressed mood was significantly associated with 
lowering of the elevated cortisol levels. With cortisol decreased by treatment to normal 
levels, continued high ACTH levels did not prevent improvement in depressed mood. 
The mechanism underlying the apparent effect of cortisol on the depressed mood in 
Cushing’s syndrome is unknown. In psychiatric patients with primary affective 
disease, behavioral and physiologic abnormalities have also been shown to be 
associated with increased cortisol levels. Thus, cortisol may play a role in the 
pathogenesis and/ or maintenance of the mood disorder in psychiatric patients as well. 
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